Biosimilars Have Driven Down Cost of Infliximab

Biosimilars have driven down the costs of originator biologics, but it isn't clear whether those savings are being passed on to patients or increasing access to the drugs.

Related Keywords

United States ,Columbus ,Ohio ,University Of Chicago ,Illinois ,Tennessee ,Urbana ,Vanderbilt University ,American ,Modan Goldman ,Davidt Rubin ,Samantha Paglinco ,Sara Horst ,Carle Illinois College Of Medicine ,American Gastroenterological Association ,Crohn Colitis Foundation ,Vanderbilt University Medical Center ,Pcrohn Colitis Congress ,Colitis Foundation ,American Gastroenterological ,Carle Illinois College ,Merative Marketscan Commercial Claims ,Nationwide Children ,Biologic Therapy ,Iologics ,Biosimilars ,Biosimilar Drugs ,Follow On Biologics ,Practice Management ,Revenue ,Insurance ,Inflammatory Bowel Disease Ibd ,Children ,Child ,Childhood ,Ediatrics ,Kids ,Medicare ,Colitis ,Crohn Amp 039s Disease ,Crohn Disease ,Egional Enteritis Crohn S ,Fellowship ,Yellows ,Grant ,Hospitals ,Nutrition ,Student ,